Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025':...

Published on 10 Dec 2024 on Benzinga · via Yahoo Finance

Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on...

Read the rest of the article

Start tracking your investments with Statfolio

The London stock market has faced recent challenges, with the FTSE 100 and FTSE 250 indices exper...

Simply Wall St. · via Yahoo Finance 16 Jan 2025

Key Insights Significantly high institutional ownership implies Kodiak Sciences' stock price is...

Simply Wall St. · via Yahoo Finance 28 Dec 2024

The UK market has recently faced challenges, with the FTSE 100 index declining due to weak trade ...

Simply Wall St. · via Yahoo Finance 16 Dec 2024

Jefferies has upgraded Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company focused on...

Benzinga · via Yahoo Finance 10 Dec 2024

Over the last 7 days, the UK market has dropped by 1.0%, but it has risen by 6.9% over the past y...

Simply Wall St. · via Yahoo Finance 15 Nov 2024

Kodiak Sciences (KOD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism abo...

Zacks · via Yahoo Finance 21 Jul 2024

Kodiak Sciences (KOD) is evaluating its lead candidate, tarcocimab, in a late-stage study for...

Zacks · via Yahoo Finance 8 Jun 2024

Kodiak Sciences Inc. KOD reported first-quarter 2024 loss per share of 82 cents, narrower than th...

Zacks via Yahoo Finance 17 May 2024

With the business potentially at an important milestone, we thought we'd take a closer look at Ko...

Simply Wall St. via Yahoo Finance 1 May 2024

Kodiak Sciences Inc. (NASDAQ:KOD) Q4 2023 Earnings Call Transcript March 28, 2024 Kodiak Sciences...

Insider Monkey via Yahoo Finance 1 Apr 2024